Director: Zoltan P. Arany, M.D., Ph.D.


Metabolic derangements, including obesity and diabetes, are currently the leading contributors to cardiovascular disease in the US and worldwide. More than a third of all Americans are obese, and one in ten have diabetes. Importantly, cardiovascular disease is the leading cause of death in the diabetic population. The Cardiovascular Metabolism Program (CMP), bridging the Institute of Diabetes, Obesity, and Metabolism (IDOM) and the Cardiovascular Institute (CVI), aims to fundamentally advance our understanding of the relationship between metabolic and cardiovascular diseases. Members of the program are taking a wide variety of approaches including human genetics, human physiology studies, iPSC and murine genetic engineering, and state-of-the-art metabolomics to address fundamental and mechanistic questions in lipid biology, vascular disease, insulin resistance, and other processes critically involved at the interface between metabolic and cardiovascular disease. The aims of the program are two-fold: 1) to unravel molecular mechanisms by which metabolic derangements lead to heart and vascular disease (and vice versa); and 2) to leverage these discoveries to develop novel diagnostic biomarkers and therapeutic targets to treat these devastating afflictions.


Full Members 



* CHOP CVI Membership